2024-09-04 - Analysis Report
## AMGN Stock Analysis

**Company Overview:** Amgen (AMGN) is a leading biotechnology company developing and delivering innovative therapies for serious illnesses.

**Performance Analysis:**

**1. Return Comparison:**

* AMGN's cumulative return is 58.57%, while the S&P 500 (VOO) has a cumulative return of 89.66%. 
* This puts AMGN at -31.09% relative to the S&P 500, or 46.06% of the way between the minimum and maximum historical divergence.

**2. Recent Price Movements:**

* Closing Price: $333.83
* 5-day moving average: $329.61
* 20-day moving average: $325.69
* 60-day moving average: $321.37

**3. Technical Indicators:**

* **RSI:** 68.97 -  Indicates the stock is currently in overbought territory.
* **PPO:** 0.17 -  Suggests a potential for price momentum, but requires further analysis.
* **Delta_Previous_Relative_Divergence:** -12.38 -  Implies a recent short-term downward trend in price movement relative to the market.
* **Expected Return:** 7.55% - Represents the potential 5-year expected return on investment. 

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-07 | 1.39 | 8.39 B$ |
| 2024-05-03 | -0.21 | 7.45 B$ |
| 2023-10-31 | 3.23 | 6.90 B$ |
| 2023-08-04 | 2.58 | 6.99 B$ |
| 2024-08-07 | 2.58 | 6.99 B$ |

* **Latest Earnings:**  The most recent earnings report for the quarter ending August 7, 2024, showed EPS of $1.39 and revenue of $8.39 billion, surpassing analyst estimates.

**5. Overall Analysis:**

* **Return:** AMGN has underperformed the S&P 500 in recent years, but it's important to consider the long-term perspective. 
* **Price:**  The current price is above all moving averages, suggesting potential momentum.
* **Indicators:** While RSI indicates overbought territory, the PPO and Delta_Previous_Relative_Divergence suggest a recent short-term downward trend, but potential for continued price momentum.
* **Earnings:** Strong recent earnings performance with significant revenue growth and exceeding analyst estimates.

**6. Conclusion:**

While AMGN has underperformed the market in recent years, the company continues to show strong earnings growth and revenue performance, supported by a robust pipeline of innovative therapies. The technical indicators suggest a potential for price momentum, but the current overbought RSI warrants caution. It is crucial to monitor AMGN's future earnings reports and other relevant news for potential catalysts to drive further price movement. Investors should carefully consider their risk tolerance and investment goals before making any decisions. 
